Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate

OBJECTIVE: To evaluate the similarities between LBEC0101 (etanercept biosimilar) and the etanercept reference product (ETN-RP) in terms of efficacy and safety, including immunogenicity, in patients with active rheumatoid arthritis despite methotrexate treatment. METHODS: This phase III, multicentre,...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuno, Hiroaki, Tomomitsu, Masato, Hagino, Atsushi, Shin, Seonghye, Lee, Jiyoon, Song, Yeong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890628/
https://www.ncbi.nlm.nih.gov/pubmed/29259050
http://dx.doi.org/10.1136/annrheumdis-2017-212172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890628/
https://www.ncbi.nlm.nih.gov/pubmed/29259050
http://dx.doi.org/10.1136/annrheumdis-2017-212172

Ejemplares similares